A detailed history of Morgan Stanley transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Morgan Stanley holds 34,012 shares of ATHA stock, worth $21,087. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,012
Previous 23,200 46.6%
Holding current value
$21,087
Previous $61,000 75.41%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.42 - $3.43 $4,541 - $37,085
10,812 Added 46.6%
34,012 $15,000
Q2 2024

Oct 17, 2024

SELL
$1.92 - $2.71 $37,054 - $52,300
-19,299 Reduced 45.41%
23,200 $61,000
Q2 2024

Aug 14, 2024

SELL
$1.92 - $2.71 $37,054 - $52,300
-19,299 Reduced 45.41%
23,200 $61,000
Q1 2024

Oct 17, 2024

BUY
$2.24 - $4.15 $43,229 - $80,090
19,299 Added 83.19%
42,499 $116,000
Q1 2024

Aug 16, 2024

SELL
$2.24 - $4.15 $15,823 - $29,315
-7,064 Reduced 14.25%
42,499 $116,000
Q1 2024

May 15, 2024

SELL
$2.24 - $4.15 $15,823 - $29,315
-7,064 Reduced 14.25%
42,499 $116,000
Q4 2023

Aug 16, 2024

BUY
$1.39 - $2.46 $36,644 - $64,852
26,363 Added 113.63%
49,563 $120,000
Q4 2023

Feb 13, 2024

SELL
$1.39 - $2.46 $17,386 - $30,769
-12,508 Reduced 20.15%
49,563 $120,000
Q3 2023

Nov 15, 2023

SELL
$1.9 - $3.16 $98,999 - $164,651
-52,105 Reduced 45.64%
62,071 $125,000
Q2 2023

Aug 14, 2023

SELL
$2.36 - $3.59 $488,994 - $743,851
-207,201 Reduced 64.47%
114,176 $336,000
Q1 2023

May 15, 2023

BUY
$2.26 - $4.22 $374,020 - $698,393
165,496 Added 106.17%
321,377 $803,000
Q4 2022

Feb 14, 2023

SELL
$2.76 - $3.71 $114,310 - $153,657
-41,417 Reduced 20.99%
155,881 $494,000
Q3 2022

Nov 14, 2022

BUY
$2.93 - $3.96 $384,345 - $519,456
131,176 Added 198.38%
197,298 $586,000
Q2 2022

Oct 27, 2022

SELL
$2.74 - $13.43 $7,315 - $35,858
-2,670 Reduced 3.88%
66,122 $202,000
Q2 2022

Aug 15, 2022

SELL
$2.74 - $13.43 $7,315 - $35,858
-2,670 Reduced 3.88%
66,122 $202,000
Q1 2022

Oct 27, 2022

BUY
$8.96 - $13.51 $23,923 - $36,071
2,670 Added 4.04%
68,792 $929,000
Q1 2022

May 13, 2022

SELL
$8.96 - $13.51 $216,177 - $325,955
-24,127 Reduced 25.97%
68,792 $929,000
Q4 2021

Feb 14, 2022

SELL
$9.17 - $16.39 $787,281 - $1.41 Million
-85,854 Reduced 48.02%
92,919 $1.21 Million
Q3 2021

Nov 15, 2021

BUY
$9.15 - $11.09 $1.64 Million - $1.98 Million
178,773 New
178,773 $1.68 Million

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $23.4M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.